Turning Point Brands Appoints Andrew Flynn as Chief Financial Officer

News by 2FIRSTS.ai

Mar.13.2024

Turning Point Brands Appoints Andrew Flynn as Chief Financial Officer

Turning Point Brands appoints Andrew Flynn as CFO, replacing Louie Reformina, effective April 1, 2024, per RTTNews.

According to RTTNews, American brand consumer goods manufacturer, marketer, and distributor Turning Point Brands company (TPB) announced the appointment of Andrew Flynn as Chief Financial Officer (CFO).

Flint will take office on April 1, 2024, replacing current CFO Louie Reformina, who is set to resign.

Flinn previously served as Chief Financial Officer at Connected Cannabis Co. and held the position of Vice President at Juul Labs before joining Turning Point Brands.

References:

[1] Turning Point Brands Names Flynn CFO

Also Read:

[1] Turning Point Brands Announces Financial Performance for 2023: Sales down by 6% in Q4

[2] Turning Point Brands Reports Decline in Sales for 2023

[3] Turning Point Brands Canada Becomes Exclusive Distributor for VPRB's HoneyStick in Canada

[4] Financial Report: Turning Point Brands Q4 2022 Results

#North America #United States #Traditional tobacco #Tobacco #Major companies

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Harm Reduction Experts Warn: FCTC COP11 Policies Risk Marginalizing the Global South

Two global tobacco harm reduction experts, in their submission to 2Firsts, argue that several COP11 policy proposals driven by high-income countries do not align with the capacities and conditions of low- and middle-income countries. They highlight research and funding gaps and call for a more equitable global support mechanism.

Nov.19

JUUL wins approval after FDA reversal of Marketing Denial Order

JUUL's regulatory journey from Marketing Denial Order to approval showcases FDA's evolving approach to e-cigarette oversight.

Nov.03 by 2FIRSTS.ai

PMI Compares Smoke-Free Policies in Three Countries: Japan and New Zealand Lead Tobacco Control, While Thailand’s Ban Stalls Harm Reduction

PMI Malaysia says Japan and New Zealand’s regulated smoke-free alternatives have hastened smoking declines, whereas Thailand’s post-2014 ban drives smokers to cigarettes or the black market—evidence, PMI argues, that pairing regulated alternatives with traditional controls could improve public health faster.

Oct.15 by 2FIRSTS.ai

U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months

The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.